On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Sangamo Biosciences Inc. (NASDAQ:SGMO), InspireMD, Inc. (NYSEMKT:NSPR), Leju Holdings Limited (NYSE:LEJU), TherapeuticsMD, Inc. (NYSEMKT:TXMD)
Latest NEWS regarding these Stocks are depicted underneath:
Sangamo Biosciences Inc. (NASDAQ:SGMO)
Sangamo Biosciences Inc. (SGMO), declared that Elizabeth Wolffe, Ph.D., Sangamo’s vice president, corporate communications, will present an overview of the Corporation’s ZFP Therapeutic® programs at 1:55pm ET on Wednesday, March 25, 2015, at the 3rd Annual Regen Med Investor Day. The meeting will be held in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, planned and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program comprises clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, in addition to offer insight into how advanced therapies could influence the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event comprises dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top corporation CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and forthcoming milestones in the adoptive T-cell therapy space.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical corporation, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States.
InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. (NSPR), a leader in embolic protection systems (“EPS”), declared that the New York Stock Exchange has accepted InspireMD’s plan to regain compliance with the NYSE MKT’s market capitalization continued listing standards. As formerly revealed, the NYSE notified the Corporation on January 20, 2015 that it had fallen below the NYSE’s continued listing standards.
Based upon a review of the compliance plan and information presented by the Corporation, the Exchange determined that the Corporation made a reasonable demonstration of its ability to make substantial progress toward regaining compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Corporation Guide by July 20, 2016. The Exchange also determined that the Corporation has resolved the continued listing deficiency with respect to Section 1003(a)(iv) of the Corporation Guide.
The Corporation will be subject to periodic review by the exchange staff during the period covered by the plan. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the plan period could result in the Corporation’s shares being delisted from the Exchange.
InspireMD seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
Leju Holdings Limited (NYSE:LEJU)
Leju Holdings Limited (LEJU), declared its unaudited financial results for the fiscal quarter and full year ended December 31, 2014.
“We are happy to report strong results for our first year as a public corporation,” said Mr. Geoffrey He, Leju’s chief executive officer. “During 2014, Leju further strengthened its O2O platform for real estate services across the primary, secondary and home furnishing markets through continuous product innovation and with a strong focus on execution. We also successfully incorporated mobile marketing into our service portfolio through our cooperation with leading social media platforms Weibo and Weixin. In a softer primary real estate market, our new mobile platform and various product launches allow us to offer differentiated advantages and deliver positive results for our clients as they turn to us for support in marketing and promoting their projects.”
“Looking ahead, we expect that China’s real estate market will continue to experience a period of change, and we remain committed to executing on our business strategies in 2015,” Mr. He continued. “We believe the e-commerce market offers unique opportunities and we plan to further grow this business through the use of mobile solutions. We will stay focused on building a transparent informational platform in the secondary listing business through the promotion of reliable home data using our verified listing model together with our brokerage partners. Furthermore, we also plan to expand our home furnishing business in 2015 through a new platform that brings together customers with individual contractors, who serve a pivotal role in home furnishing projects. We believe that our service-oriented business model and strong online and offline execution make us well-positioned to address our clients’ marketing needs and generate and capture further growth.”
“We are reporting strong top-line growth, with our e-commerce business in particular delivering another year of high proceed growth,” said Ms. Min Chen, Leju’s chief financial officer. “We generated strong operating cash flows for the year which will support the corporation’s operations and planned investments in 2015.”
Leju Holdings Limited (LEJU) is a leading online-to-offline, or O2O, real estate services provider in China, offering real estate e-commerce, online advertising and online listing services. Leju’s integrated online platform comprises various mobile applications together with local websites covering more than 250 cities, improved by complementary offline services to facilitate residential property transactions.
TherapeuticsMD, Inc. (NYSEMKT:TXMD)
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare corporation, declared the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.
Angus C. Russell served as CEO of Shire PLC, a biopharmaceutical corporation, from June 2008 until April 2013. Russell served as the chief financial officer of Shire from 1999 to 2008 and also served as executive vice president of global finance. Preceding to joining Shire, Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of vice president, corporate finance at AstraZeneca. He is a chartered accountant, having qualified with what is now PriceWaterhouseCoopers LLP. Russell also serves as a director of Mallinckrodt PLC and BioTime Inc. and as the chairman of the board of Revance Therapeutics Inc. Russell formerly served as a director of Shire PLC, Questcor Pharmaceuticals Inc. and InterMune Inc.
- Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011. He also served as global head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012 and served as chairman of the board for a number of BI companies. Formerly, Carroll held positions of increasing responsibility with Merck & Co. Inc. from 1976 to 2001, counting manufacturing, international (Japan) and marketing and sales. He left Merck serving as its executive vice president for customer marketing and sales of the U.S. Human Health Division. From 1972 to 1976, Carroll served in the United States Air Force. Carroll has formerly served on the board of directors for a number of organizations, counting Accredo Health Group Inc., Vivus Inc., Durata Therapeutics Inc., and Gwynedd Mercy College, in addition to PhRMA. He presently serves as a director of Mallinckrodt PLC.
Finizio commended the contributions of outgoing director Randall Stanicky, who presently serves as managing director of global equity research, with a focus on specialty pharmaceuticals, at RBC Capital Markets.
“We would like to thank Randall for his assist, contributions and commitment to TherapeuticsMD as a valued board member who will be missed,” Finizio said. “Randall’s unique experience and extensive knowledge in this sector have been very assistful as we advance our hormone therapy portfolio and gain greater leadership in the women’s healthcare space. We sincerely thank Randall for his tenure with us.”
TherapeuticsMD, Inc. is an innovative healthcare corporation focused on developing and commercializing products exclusively for women. With its patented SYMBODA™ technology platform, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
